These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease. Brys I, Nunes J, Fuentes R. Eur J Neurosci; 2017 Aug; 46(3):1906-1917. PubMed ID: 28370471 [Abstract] [Full Text] [Related]
3. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432 [Abstract] [Full Text] [Related]
4. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone. Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E. Neuroscience; 2012 Feb 17; 203():170-9. PubMed ID: 22198020 [Abstract] [Full Text] [Related]
6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H. J Neurochem; 2004 Oct 17; 91(2):451-61. PubMed ID: 15447678 [Abstract] [Full Text] [Related]
7. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. Naughton C, O'Toole D, Kirik D, Dowd E. Behav Brain Res; 2017 Jan 01; 316():160-168. PubMed ID: 27585560 [Abstract] [Full Text] [Related]
8. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease. Coune PG, Bensadoun JC, Aebischer P, Schneider BL. J Parkinsons Dis; 2011 Jan 01; 1(4):373-87. PubMed ID: 23939344 [Abstract] [Full Text] [Related]
12. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Van der Perren A, Toelen J, Casteels C, Macchi F, Van Rompuy AS, Sarre S, Casadei N, Nuber S, Himmelreich U, Osorio Garcia MI, Michotte Y, D'Hooge R, Bormans G, Van Laere K, Gijsbers R, Van den Haute C, Debyser Z, Baekelandt V. Neurobiol Aging; 2015 Mar 01; 36(3):1543-58. PubMed ID: 25599874 [Abstract] [Full Text] [Related]
13. Therapeutic effects of repetitive transcranial magnetic stimulation in an animal model of Parkinson's disease. Lee JY, Kim SH, Ko AR, Lee JS, Yu JH, Seo JH, Cho BP, Cho SR. Brain Res; 2013 Nov 06; 1537():290-302. PubMed ID: 23998987 [Abstract] [Full Text] [Related]
16. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ. J Neurochem; 2007 Mar 06; 100(6):1449-57. PubMed ID: 17241127 [Abstract] [Full Text] [Related]
20. Effect of optogenetic modulation on entopeduncular input affects thalamic discharge and behavior in an AAV2-α-synuclein-induced hemiparkinson rat model. Moon HC, Won SY, Kim EG, Kim HK, Cho CB, Park YS. Neurosci Lett; 2018 Jan 01; 662():129-135. PubMed ID: 29037791 [Abstract] [Full Text] [Related] Page: [Next] [New Search]